Stacey E. Tarvin

<i>HLA-DRB1*11</i> and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis

Michael J. Ombrello, Elaine F. Remmers, Ioanna Tachmazidou et al. · Proceedings of the National Academy of Sciences · 2015 · 185 citations · Full text

Life Sciences, Genetics, Immunology +17

Recognition, Diagnosis, and Treatment of Histoplasmosis Complicating Tumor Necrosis Factor Blocker Therapy

Chadi A. Hage, Suzanne L. Bowyer, Stacey E. Tarvin et al. · Clinical Infectious Diseases · 2009 · 181 citations

Medicine, Immunology, Infectious Diseases +15

Randomized, Double‐Blind, Placebo‐Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis

Norman T. Ilowite, Kristi Prather, Yuliya Lokhnygina et al. · Arthritis & Rheumatology · 2014 · 163 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America

Kelly Rouster‐Stevens, Harry L. Gewanter, Grant Syverson et al. · Pediatric Rheumatology · 2017 · 54 citations · Full text

Medicine, Clinical Sciences, Pediatrics +12

Thoracoscopy-assisted Heller myotomy for the treatment of achalasia: results of a minimally invasive technique

Kenneth A. Kesler, Stacey E. Tarvin, Jo Ann Brooks et al. · The Annals of Thoracic Surgery · 2004 · 19 citations · Full text

Medicine, Surgery, General Surgery +4